Organon Reports Q3 Adjusted Net Income of $256 Million; Adjusted EPS $0.94

What happened

Organon reported third-quarter 2026 adjusted net income of $256 million and adjusted diluted earnings per share of $0.94. GAAP net income was $164 million, up from $160 million a year earlier, while adjusted net income fell from $263 million.

Confirmed

Global impact / market context

Adjusted profit and adjusted EBITDA, which means earnings before interest, taxes, depreciation and amortization, both fell, showing weaker core profitability. Because the merger with Sun Pharmaceutical is pending, Organon suspended its usual earnings call, leaving investors with fewer explanations for the decline.

Analyst inference

Organon's adjusted gross margin, which means the share of revenue left after production costs, slipped to 59.6% from 60.3%. Combined with lower adjusted EBITDA and suspended guidance calls during the pending merger, this points to softening profit per sale and limited visibility for investors.

Analyst inference

What to watch

1. Organon suspended its customary earnings release and conference call while its merger with Sun Pharmaceutical Industries Limited is pending, so investors will rely on filed supplemental results for detail. Confirmed
2. Watch whether adjusted EBITDA margin, which means operating profit as a share of sales, keeps falling below 31.9%, since further declines would signal eroding profit per sale. Analyst inference
3. Watch for merger updates with Sun Pharmaceutical, including deal terms and timing, because completion could change Organon's ownership, cost structure and how its shares trade. Proposed

Evidence

• Original source link unavailable